Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene ...

The FDA has approved Zevaskyn, the first gene-modified cellular therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosis, a rare genetic skin disorder. Made by Abeona ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the American Association for Cancer Research, Verily’s Parkinson’s dataset, the ...

The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.

Gilead held dinners to promote its HIV medications at expensive restaurants that federal authorities claim were “wholly inappropriate” venues, Stat reported. Gilead said it settled to avoid the cost ...

The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also ...

Abeona Therapeutics' Zevaskyn, a cell therapy based on engineered keratinocytes harvested from patients, has been approved in ...

ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Zevaskyn™ Approved by FDA On April 29, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) ...

With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...